; "banner")
October 8, 2026
Alpha-9 Oncology Announces Presentation of Data for its GRPR-Targeting Imaging Compound 68Ga-A9-6217 at the European Association of Nuclear Medicine (EANM) 2026 Annual Congress
BOSTON, Mass. and VANCOUVER, British Columbia, October 8th, 2026 – Alpha-9...
September 8, 2026
Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors
Phase 1 study evaluates distinct 225Ac and 177Lu compounds in breast...
December 4, 2025
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the...
November 10, 2025
Alpha-9 Oncology Appoints Paul Blanchfield as Chief Executive Officer
BOSTON, Mass. and VANCOUVER, British Columbia, November 10, 2025 – Alpha-9...
April 24, 2025
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025...
October 23, 2024
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals
BOSTON, Mass. and VANCOUVER, British Columbia, October 23, 2024 – Alpha-9...
